UNSPSC 51162039: Vilanterol/Fluticasone furoate

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema)

UNSPSC 51162039 Vilanterol/Fluticasone furoate is a Commodity code. The recent state and local procurement activity under this code shows no concrete solicitation opportunities. The opportunities tagged to this code in the source record include a county purchasing department relocation notice, a reverse trade show networking event in Marion County, a vendor forum in Williamson County, and multiple other state and local business development events and informational sessions—none of which involve actual procurement of Vilanterol/Fluticasone furoate or closely related pharmaceutical products. One entry nominally references Naloxone and drug deactivation systems for Seminole County (IFB 60459723LAS, response due July 26, 2023), and another describes BLS/ALS pharmaceuticals and medical supplies for the City of Tucson Fire Department (RFP 260217, response due June 24, 2026), but these are distinct therapeutic categories unrelated to the vilanterol/fluticasone combination respiratory agent specified in the code. The pharmaceutical procurement activity in the source record—Seminole County's naloxone procurement, Tucson's emergency medical services pharmaceuticals, and the MMCAP generic multi-source pharmaceuticals RFP for state and local facilities—does not evidence demand for this specific product combination.

The code shows no measurable recent state and local procurement volume and should be monitored rather than pursued at this time. State and local health departments, fire departments, and emergency medical service operations are active buyers of pharmaceuticals and medical supplies, but current solicitation activity does not reflect procurement of inhaled combination corticosteroid-long-acting beta-agonist products. Activity across state and local systems is concentrated in emergency medical supplies, naloxone distribution, and generic multi-source pharmaceutical contracts rather than branded respiratory therapies, suggesting limited near-term opportunity under this specific code.